SGL Investment Advisors Inc. Has $235,000 Stock Position in Insulet Corporation $PODD

SGL Investment Advisors Inc. cut its position in shares of Insulet Corporation (NASDAQ:PODD) by 71.9% in the second quarter, Holdings Channel reports. The firm owned 792 shares of the medical instruments supplier’s stock after selling 2,024 shares during the period. SGL Investment Advisors Inc.’s holdings in Insulet were worth $235,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Knights of Columbus Asset Advisors LLC grew its position in Insulet by 0.5% in the second quarter. Knights of Columbus Asset Advisors LLC now owns 17,237 shares of the medical instruments supplier’s stock worth $5,416,000 after acquiring an additional 78 shares in the last quarter. Highland Capital Management LLC acquired a new position in shares of Insulet during the 2nd quarter valued at about $1,479,000. QRG Capital Management Inc. raised its position in shares of Insulet by 16.2% in the second quarter. QRG Capital Management Inc. now owns 2,358 shares of the medical instruments supplier’s stock valued at $741,000 after purchasing an additional 328 shares during the period. Franklin Street Advisors Inc. NC acquired a new position in Insulet in the 2nd quarter valued at $346,000. Finally, Ascent Group LLC acquired a new position in Insulet during the 2nd quarter worth $203,000.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Stock Up 0.8%

Shares of NASDAQ:PODD opened at $311.69 on Tuesday. Insulet Corporation has a 52 week low of $225.37 and a 52 week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The company’s fifty day moving average is $321.73 and its 200-day moving average is $299.30. The company has a market capitalization of $21.94 billion, a PE ratio of 94.74, a P/E/G ratio of 2.57 and a beta of 1.40.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s quarterly revenue was up 32.9% on a year-over-year basis. During the same period last year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Saturday, September 27th. Citigroup reaffirmed a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Finally, Royal Bank Of Canada upped their price target on Insulet from $330.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $346.83.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.